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1. Introduction
The FDA approvals of ipilimumab targeting the cytotoxic T lymphocyte-associated antigen 4
(CTLA-4), pembrolizumab targeting the programmed cell death protein 1 (PD-1), BRAF
inhibitors vemurafenib and dabrafenib, and MEK inhibitor trametinib represent significant
milestones in more effective treatment of advanced melanoma. However, it is clear that the
use of these single-agent therapies have limitation clinically. For example, ipilimumab only
showed 4.5% objective response rate when used alone in a Phase II clinical trial [1]. The efficacy
of vemurafenib lasts only 6.7 months before the disease relapses especially in patients with
metastatic melanoma [2]. Therefore, rational combination approaches are strongly preferred
in order to improve the overall patient progression-free survival (PFS), overcome or delay the
development of multi-drug resistance and reduce the incidents of side effects [3-6].
In this chapter, we will summarize the emerging combination therapy approaches from both
clinical trial and preclinical research in the past five years.
2. Combination of kinase inhibitors for melanoma treatment
2.1. Combined inhibitions targeting components within the Mitogen-Activated Protein
Kinase (MAPK) signaling pathway
2.1.1. Targeting BRAF: Mechanism of action, toxicity and drug resistance
BRAF is a serine/threonine growth signal transduction protein kinase from RAF family which
plays important roles in the RAS/RAF/MEK/ERK pathway and directs cell division, prolifer‐
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ation and secretion [7]. BRAF inhibitors (BRAFi) are ATP-competitive ligands which inactivate
the function of BRAF protein by either stabilizing the inactive form of kinase domain (sorafe‐
nib) or preferentially inhibit the active form of the kinase (vemurafenib, dabrafenib) [8, 9].
Various mutations of BRAF gene have been identified in cancers including melanoma,
colorectal and ovarian cancer. Around 60% of human melanoma adopted the T1799A trans‐
version in exon 15, which lead to BRAFV600E mutation and the over-activated monomer
phosphorylation for BRAFV600E [9, 10]. The two FDA approved BRAFi (Vemurafenib and
dabrafenib) selectively and potently block the activation of BRAFV600E and thus inhibit the
MAPK signaling pathway. These drugs show very high clinical efficacy in metastatic mela‐
noma patients harboring the BRAFV600E mutation [11-13]. Interestingly, in a clinical study which
treated 43 patients with any V600 BRAF mutation including the rare V600R variant, five out
of the six melanoma patients having V600R mutation had clinical response to the therapy of
vemurafenib or dabrafenib (response rate 86%) [14].
Figure 1. The mechanisms of BRAF inhibitor vemurafenib (Vem) action, toxicity and the interaction between melano‐
ma cells with T lymphocytes.
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However, wide type BRAF melanoma tumors do not respond to vemurafenib or dabrafenib
inhibition, although they are sensitive to the MEK inhibitors [9]. Paradoxically, in cells with
RAS mutation and wild-type BRAF, treatment with vemurafenib or dabrafenib will promote
the formation of BRAF-CRAF heterodimer and lead to the activation of subsequent MEK/ERK
signaling and cell proliferation as shown in Figure 1 [5]. This mechanism is used to explain the
observation of typical clinical side effects associated with the use of vemurafenib: nearly 25%
of patients developed skin lesions and even cutaneous squamous cell carcinoma (CSCC). In
addition, in vitro study has revealed that vemurafenib inhibits multiple off-target kinases
including c-Jun N-terminal kinase (JNK), suppresses JNK-dependent apoptosis, and generates
CSCC toxicity [15].
2.1.2. Mechanisms of resistance to BRAF inhibition
In general, due to alternative pathway activations and inter-and intra-patients melanoma
genetic heterogeneity, various mechanisms of resistance to BRAF inhibition have been
identified [10, 16-19]. As we mentioned before, melanoma tumors bearing wide type BRAF are
intrinsically resistant to vemurafenib and dabrafenib. Tumor micro-environment also con‐
tributes to the innate resistance to BRAF inhibition in melanoma. For example, stromal cells
secrete hepatocyte growth factor (HGF), which activates the HGF-receptor MET, MAPK and
PI3K-AKT pathways [20].
Eventually, nearly all BRAF mutated melanoma tumors develop acquired drug resistance
upon treatment with BRAF inhibitors. The disease progression arises as early as two-month
continuous treatment [18, 19]. The mechanisms of acquired resistance to BRAF inhibition can
be generalized into two categories: BRAFV600E-bypass mechanisms and MAPK-bypass mech‐
anisms.
First, the BRAFV600E-bypass mechanisms reactivate MAPK signaling and lead to ERK-depend‐
ent tumor cell survival and proliferation (Figure 2A). COT, which is coded by gene MAP3K8,
is a MEK kinase. The overexpression of COT or amplification of MAP3K8 directly activates
MEK signaling without the participation of RAF protein [21]. The mutant of MEK1C121S
increases catalytic capability and circumvents BRAF to activate basal level of ERK phosphor‐
ylation [22]. Before the treatment of vemurafenib or dabrafenib, melanoma cells with
BRAFV600E mutation have over-activated monomer BRAF/MEK/ERK cascade which forms an
ERK-dependent negative feedback loop. This negative feedback loop reduces the expression
of the active RAS-GTP. In the presence of vemurafenib or dabrafenib, ERK phosphorylation
level is rapidly reduced and the feed-back suppression on RAS activation is abolished (Figure
1). Therefore, eventually the ERK cascade level is restored through RAS over-activation. NRAS
mutants including NRASQ61K and NRASQ61R can drive ERK activation through ARAF or CRAF
homo-or hetero-dimers which are alternative MEK activators [23]. The combinations of BRAF
inhibition plus MEK or ERK inhibition have showed efficacy of overcoming the resistance
through these BRAF V600E-bypass mechanisms [24-26], leading to the recent FDA approval of
dabrafenib plus trametinib combination therapy for advanced melanoma.
Second, the MAPK-bypass mechanisms allow melanoma cells to escape from the cytotoxicity
of BRAF or MEK inhibition through the activation of ERK-independent survival pathways
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(Figure 2B). The PI3K-AKT signaling pathway can be activated through the overexpression of
receptor tyrosine kinases (RTKs), for example, insulin-like growth factor 1 (IGF-1) receptor
(IGF-1R) and platelet-derived growth factor receptor beta (PDGFRβ) [27]. The elevated levels
of IGF-1R, PDGFRβ or HGF can also stimulate another receptor tyrosine kinase, MET, and
increase the activity of PI3K. Phosphatase tensin (PTEN) is a negative regulator of PI3K. The
PTEN loss-of-function mutation induces the resistance of BRAF inhibition and reduces the PFS
of dabrafenib therapy in melanoma patients due to the PI3K activation [28]. Moreover, the
upregulation of cyclin D1 can activate cyclin-dependent kinase 4 (CDK4) and 6 (CDK6) and
make melanoma cells less dependent on MAPK signaling in cell cycle progressing [29].
Figure 2. The mechanisms of acquired resistance to BRAF inhibition.
Additionally, Jaehyuk Choi et al has reported a BRAFL505H mutation which changes an amino
acid residue in BRAF-vemurafenib interface and causes the resistance to vemurafenib treat‐
ment in vitro [30]. Since vemurafenib is a substrate of the ATP-binding cassette sub-family G
member 2 (ABCG2), the overexpression of ABCG2 in BRAFV600E melanoma cell lines has caused
the increasing of vemurafenib efflux in vitro [31]. The elucidation on the mechanism of
acquired-resistance to BRAFi opens a door to rationally design and explore the proper
combination strategies to overcome or delay the development of BRAFi resistance.
2.1.3. Targeting MEK: Mechanism of action, toxicity and resistance
Trametinib, which is approved by FDA in May 2013 as a monotherapy agent against advanced
melanoma with BRAFV600E and BRAFV600K mutations, is a first-in-class, orally available,
allosteric (non-ATP-competitive) MEK1/MEK2 inhibitor (MEKi) [32, 33]. It selectively inhibits
Melanoma – Current Clinical Management and Future Therapeutics202
MEK, the down-stream kinase protein of RAF in the RAS-RAF-MEK-ERK pathway. As a result,
melanoma cells with acquired resistance to BRAFi are commonly cross-resistant to MEKi such
as trametinib or selumetinib, another selective allosteric MEKi [24, 34]. This mechanism
explains the clinical trial results in which trametinib monotherapy fails to significantly benefit
patients who have already developed acquired BRAFi resistance [35]. In contrast to the use of
a BRAFi, no CSCC side effects are observed among the patients received trametinib treatment
in clinical trials [13, 32]. However, similar to the use of vemurafenib, disease progression occurs
within 6-7 months in patients receiving single-agent trametinib treatment [36]. Nevertheless,
a retrospective analysis of 23 patients, who were first treated with MEKi and upon progression
with a selective BRAFi, shows that the median time to progression (TTP) has been prolonged
to 8.9 months from 4.8 months using a single-agent MEKi or 4.4 months for a single-agent
BRAFi treatment, respectively [37]. However, a recent clinical trial indicated that if melanoma
patients were treated with a BRAFi first then MEKi therapy, no confirmed response was
observed [35]. This indicates that optimal treatment schedule and sequence is important for
the melanoma therapy targeting the MAPK pathway.
2.1.4. Drug combination targeting MAPK pathway: From lab bench to clinical practice
Given that the mechanisms of tumor cells develop resistance to BRAFi partially by reactivating
the ERK cascade and side effects such as CSCC are RAF-dependent, combining BRAFi with
MEKi has attracted lots of research interest in order to further block the MAPK signaling
pathway. In vitro and murine models first show the synergistic anti-proliferation and anti-
tumor growth effects using the combined BRAFi and MEKi treatment [9, 27, 38, 39]. Further,
this combination overcomes the acquired resistance to BRAFi [27, 38] in both cellular based
assay and mouse xenograft models. In addition, the combined inhibition of BRAF-MEK
suppresses the paradoxical BRAFi-induced MAPK signal elevation in melanoma cells and
reduces the incidences of skin lesions in a rat model [9].
When it comes to the clinical trial data, the combined inhibition of BRAF-MEK has presented
significant improvements of major patient benefits (PFS and overall survival). A phase I/II trial
(ClinicalTrials.gov, NCT1072175) investigated the combination of oral dabrafenib (150 mg
twice per day) plus oral trametinib (1 or 2 mg daily) (combination 150/1 and 150/2) versus
monotherapy of dabrafenib (150 mg twice per day) over 108 metastatic melanoma patients
bearing either V600E (92 patients) or V600K (16 patients) BRAF mutation [12, 36]. Median PFS
in combination 150/2 group reached 9.4 months, compared to 5.8 months in the dabrafenib
monotherapy group (hazard ratio 0.39, 95% confidence interval 0.25 to 0.62). The incidence of
CSCC adverse events among combination 150/2 group is non-significantly lower than that
among monotherapy group (7% versus 19%, P=0.09). But more frequent cases of pyrexia which
is not common in trametinib single treatment have been reported in combination 150/2 group
(71%, with recurrent rate 79%), as compared with dabrafenib monotherapy group (26%) [40].
These promising data lead to an accelerated FDA approval of the combination of dabrafenib
(BRAFi) and trametinib (MEKi) for the treatment of unresectable or metastatic melanoma
patients with BRAF V600E or V600K mutation, although further phase III studies with
recruitment of more patients comparing the combination therapy with dabrafenib or vemur‐
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afenib single treatment (ClinicalTrials.gov, NCT01584648, NCT01597908) are still being
assessed.
In addition, several ongoing phase I/II clinical trials now have shown that generally the
combination of other BRAFi and MEKi is well tolerated in patients with or without receiving
BRAFi treatment before (ClinicalTrials.gov, NCT01271803 vemurafenib (BRAFi)+cobimetinib
(MEKi), NCT01543698 LGX818 (BRAFi)+MEK162 (MEKi)) [41-43] and overall response rate
has increased comparing to the monotherapy groups, although the anti-tumor efficacy data
haven’t been released.
2.2. Combination targeted therapy using Phosphatidylinositol 3-Kinase (PI3K)/AKT/
mammalian Target of Rapamycin (mTOR) inhibitors
The activation of PI3K/AKT/mTOR pathway have been widely proved to be one of the major
mechanisms of intrinsic or acquired resistance to both DNA-methylation agents (e.g. dacar‐
bazine) and targeted BRAF inhibitor therapy (Figure 2). Some cell lines that are cross-resistant
to both BRAFi and MEKi, are still sensitive to the inhibition of AKT/mTOR [34]. On the other
hand, mechanistic study revealed evidences of a negative crosstalk between RAF/MEK/ERK
and PI3K/AKT/mTOR pathways through RAS kinase. Therefore, when the downstream
mTOR function is blocked, PI3K will be able to activate MAPK pathway via a switch of RAS
[44, 45]. These investigations suggest a promising combination strategy of targeting MAPK
pathway together with PI3K/AKT/mTOR cascade. Several preclinical studies widely proved
that in MAPK inhibition sensitive melanoma cell lines, co-targeting PI3K/AKT/mTOR
effectively induces cancer cell apoptosis with down-regulated anti-apoptotic BCL-2 family
proteins [34, 46-48]. Such a co-targeting strategy can also postpone the emergence of acquired
resistance to BRAFi dabrafenib mediated by PTEN mutation or disruption [49, 50]. Further,
the dual inhibition of two pathways has successfully overcome NRAS mutation mediated
resistance to MAPK blockade in vitro and induced xenograft tumor regression in vivo [34, 38,
51]. Finally, the combination of vemurafenib (BRAFi) or selumetinib (MEKi) with BEZ235 (dual
PI3K and mTOR1/2 inhibitor) has been shown to overcome the PDGFRβ-driven resistance to
MAPK pathway inhibition [52].
A series of Phase I studies have evaluated the clinical relevance of the combination therapy
which co-targets PI3K/AKT/mTOR and RAF/MEK/ERK pathways in terms of the incidence on
severe side effect and anti-tumor efficacy in 236 patients. These patients have advanced cancers
including melanoma, colorectal, pancreatic and non-small cell lung cancers. Results from three
combination groups (AKTi MK2206+MEKi selumetinib, NCT01021748; AKTi
GSK2141795+MEKi trametinib, NCT01138085; mTOR inhibitor everolimus+MEKi trametinib,
NCT 00955773) are compared to the single treatment groups [53]. Overall, the combination
therapy did not provide significant increase of tumor control rate (64.6% for combination,
52.7% for monotherapy, P=0.16), although all five colorectal patients with co-activation of both
pathways in combination group achieved tumor regression to varied extent between 2% and
64%. However, this combination strategy causes significant higher rates of drug-related grade
III and above side effects (53.9% for combination, 18.1% for monotherapy, P < 0.001). Further‐
more, two clinical trials which involve the combination therapy of BRAFi or MEKi with AKTi
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DNE3 recently have been terminated due to the safety concerns of the toxic properties of DNE3
(ClinicalTrials.gov, NCT02087254 and NCT02095652). Nevertheless, in another ongoing phase
I/II trial which measures the safety and efficacy of a well-tolerated pan-PI3K inhibitor BKM120
combined with vemurafenib therapy, preliminary data reveals that a vemurafenib-refractory
melanoma patient with PTEN expression achieved a 35.9% reduction in target tumor (Clini‐
calTrials.gov, NCT01512251) [54]. In general, drug-related toxicity is one of the major issues
for this cross-pathway targeted combination therapy and patients genetic profiling is very
important to achieve the maximum objective response.
2.3. Combining targeted therapy with anti-angiogenic agents
Melanoma is a vascular tumor. The abnormal expression of the epidermal growth factor (EGF)
family protein and the up-regulation of EGFR-mediated alternative survival pathway have
critically shaped the response of melanoma to the current chemotherapy agents [55-58]. In a
recent study by Sun et al, six out of sixteen melanoma cell lines display acquired EGFR
expression after the development of resistance to BRAFi and MEKi [59]. Even before the FDA
approval of BRAFi and MEKi, the combination of bevacizumab, a recombinant human
monoclonal antibody VEGF inhibitor, with a specific chemotherapy agent (for example,
fluorouracil [60] or fotemustine[61]), has become a first-line treatment for metastatic melanoma
patients. Clinical trials that study the combination of anti-angiogenic agents with cytotoxic
agents have achieved promising anti-tumor activity, although tolerability issues exist [62].
VEGF blockage has been shown to enhance the efficacy of a GM-CSF-secreting immunother‐
apy in vitro [63]. In addition, a VEGF receptor-2 inhibitor, semaxanib, prolonged both the
complete and partial response time of an immunomodulatory drug, thalidomide, over 10
recurrent metastasis melanoma patients without showing significant drug-drug interaction
toxicity in a phase II trial [64].
Along with the rapid development of targeted melanoma therapeutics, the combined inhibi‐
tion of VEGFR plus PDGFR or mTOR has shown synergy anti-tumor effects on mouse models
of B16 metastatic melanoma without increasing toxicity [65, 66]. A large-scale, unbiased drug
screening study, which aims to discover effective genotype selective combinatorial therapeu‐
tics of vemurafenib-resistant BRAF and RAS mutant melanoma, identifies a triple BRAF+EGFR
+AKT inhibition as highly effective approach [3]. In the year of 2010, combination of bevaci‐
zumab with an mTOR inhibitor, everolimus, was evaluated in a phase II trial for patients with
metastatic melanoma [67]. The treatment was well tolerated in most patients. Seven out of fifty-
seven patients (12%) receiving combination therapy have shown major responses, although
the median PFS was only 4 months. This year (2014), in a phase II trial that combines bevaci‐
zumab and sorafenib, which is an inhibitor of both RAF kinase and VEGFR-2/PDGFRβ
signaling, no objective tumor responses are seen in all the fourteen patients receiving treatment
[68, 69]. Interestingly, the median TTP of patients with low VEGF (<300 pg/ml) was longer than
that of patients with high VEGF (50 weeks versus 15 weeks, P=0.02). Therefore, the levels of
VEGF in patients do influence the tumor progression profile (ClinicalTrials.gov,
NCT00387751).
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2.4. Combination therapy using targeted therapy with versatile chemotherapy agents
Since the abnormally activated (phosphorylation) of ERK and AKT constitutively exist in
melanoma cells and promote the disease progression especially metastasis, blocking ERK or
AKT pathway can sensitize the metastatic melanoma to the apoptosis induced by chemother‐
apeutic agents including cisplatin, temozolomide, DTIC and arsenite [70-72]. With the
understanding of tumor biology about the programmed cell apoptosis and the rapid devel‐
opment of agents that can trigger the cell death process in melanoma, the combination of a
MAPK inhibitor with a BCL-2 inhibitor (ABT-737 [73] or navitoclax [74]), or a MDM2 antago‐
nist nutlin-3 [75], has synergistically induced apoptosis of melanoma in vitro and suppressed
xenograft tumor growth in vivo. A comparative analysis on the samples collected from patients
receiving vemurafenib or dabrafenib/trametinib combination treatment showed that BCL-2
expression level is closely related to the onset of MAPK inhibition resistance [74]. Clinical trials
are being conducted to investigate the combination of BCL-2 inhibitor (BH3 mimetics)
navitoclax and vemurafenib [74].
Due to the heterogenetic characteristics of melanoma disease, Vultur A et al [76] recently report
that MEK or BRAF inhibition can potentially strengthen the invasion property of human
melanoma cells by about 20%. As a result, co-inhibiting kinases that are actively involved in
cell invasion process, such as RTK, STAT3 and Src, together with MEK inhibition has effectively
abolished the invasive phenotype and further caused the tumor cell death in a 3D matrix
model.
Metformin, a biguanide oral anti-diabetic drug, has been discovered with antitumor activity
in various cancer types including melanoma. Although the exact mechanisms remain to be
elucidated, accumulating data suggest that metformin can activate AMP-activated protein
kinase (AMPK) and thus increase the activities of VEGF and ERK in BRAFV600E mutated
melanoma cells [77]. AMPK negatively regulates malignant cell proliferation and viability [78].
The combination of vemurafenib and metformin has shown synergistic anti-proliferative
effects on six out of eleven tested BRAFV600E melanoma cell lines [79]. Pilot clinical studies that
evaluate the safety and efficacy of metformin combination therapies (plus dabrafenib or
trametinib) are now recruiting patients (ClinicalTrials.gov, NCT0184000, NCT02143050).
Unlike the cutaneous melanoma, over-activation of MAPK pathway in uveal melanoma is
associated GNAQ or GNA11 mutations instead of BRAF or RAS mutations [80]. Protein kinase
C (PKC) inhibitors such as enzastaurin or AEB071 induce apoptosis in GNAQ-mutant but not
in GNAQ wild type uveal melanoma cells [81]. The level of ERK phosphorylation also
decreases in these cells when they are treated using PKC inhibitors [81]. Chen et al. has recently
confirmed the synergy of the combination using a PKC inhibitor with a MEKi (PD0325901 or
MEK162) in GNAQ/11 mutant uveal melanoma cells [82].
Understanding the mechanisms of resistance to MAPK inhibition in melanoma can lead to
rational  combination  designs  in  order  to  overcome  acquired  drug  resistance  to  BRAF
inhibitors.  For example,  our lab recently identified a synergistic combination in which a
novel tubulin inhibitor ABI-274 combined with vemurafenib could overcome the acquired
vemurafenib-resistance [83]. This combination treatment effectively arrested the vemurafe‐
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nib-resistant melanoma cells in both G0/G1  and G2/M phases and induced strong apopto‐
sis through the down-regulation of AKT phosphorylation. In addition, the combination of
a  MEKi  (TAK-733)  with  an  Hsp90  inhibitor  (ganetespib)  induces  tumor  regressions  in
vemurafenib-resistant xenograft models also through the depletion of AKT signaling [84].
With  the  finding  that  up-regulated  cyclin  D1  expression  is  critical  for  the  survival  of
vemurafenib-resistant  cells,  a  selective  inhibitor  of  cyclin  dependent  kinase  (CDK)  4/6,
LY2835219, has been reported to overcome the reactivation of MAPK signaling in vemura‐
fenib-resistant BRAFV600E melanoma [85].
3. Combinations involving immunotherapy in melanoma treatment
3.1. Combined blockade of immuno-checkpoints
Given the unsatisfactory results of cytokine-based melanoma immunotherapy (recombinant
interferon-α 2b and high dose interleukin-2) in the past decade, the development and approval
of ipilimumab (anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) monoclonal
antibody) in 2013 have marked a breakthrough of immune-checkpoints blockade therapy [86].
CTLA-4 (CD152) expresses on the surface of active T-lymphocytes and inhibits the initial T-
cell proliferation and migration to the tumor tissue [87]. CTLA-4 antibodies preferentially
target the suppressive regulatory T cells and prevent them from being hijacked by tumors [88].
In a double-blinded phase III study in 676 patients with pretreated and refractory metastatic
melanoma, ipilimumab at the dose of 3 mg/kg achieved a median OS of 10 months [86]. In a
meta-Kaplan-Meier-analysis of data collected from 1,861 melanoma patients in a clinical trial,
a plateau of survival curve starts from around 3 years after ipilimumab treatment with follow-
up extends as long as ten years, indicating a long-term survival benefits of ipilimumab therapy
(ClinicalTrials.gov, NCT01844505). In addition, ipilimumab showed good tolerance and
efficacy in several other clinical trials in which it was combined with a standard chemotherapy
agent such as dacarbazine, fotemustine or temozolomide [89].
Another success of immune-check point blockade strategy is the development of anti-
programmed death-1 (PD-1) antibodies, represented by pembrolizumab (MK-3475) and
nivolumab [90, 91]. Pembrolizumab, as the first-in-class PD-1 inhibitor, has obtained FDA
approval in September 2014 for patients with advanced or unresectable melanoma. The cDNA
of PD-1 (CD279) is first cloned in programmed death T cells although PD-1 itself does not
directly induce apoptosis. PD-1 is over-expressed on the surface of dysfunctional activated T-
cells and contributes to the maintenance of T cell dysfunction (exhaust) phenotype and
proliferation disability in the tumor site [92]. Two counter receptors of PD-1 have been
identified: PD-L1 and PD-L2. PD-L1 is more frequently and exclusively expressed in various
tumor cells; therefore, antibodies targeting PD-L1 (MPDL3280A and BMS-936559) also have
anti-tumor activity in advanced cancer including melanoma [91, 93]. The PD-1-PD-L1 ligation
retards the recognition and destroying of tumor cells by CD8+cytotoxic T-lymphocytes [87].
As a result, blocking PD-1 or PD-L1 will reverse the cancer cell immune escape. Because both
CTLA-4 and PD-1 are key negative receptors that cooperatively modulate the adaptive
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immune response in tumor progression, their combination has been shown to be synergistic
in B16 melanoma tumors without overt toxicity [94].
In a cohort phase I trial that studied the concurrent administration of ipilimumab and
nivolumab to 53 patients with advanced, treatment-resistant melanoma, more than 80% tumor
reduction was observed in 30% patients after 12 weeks treatment at the maximum tolerated
dose. Twenty-one out of fifty-three patients had objective responses and over 80% of these
patients had tumor regression. Grade 3/4 adverse events are diagnosed in 53% patients but the
toxicities are manageable with immune-suppressants [95]. Consequential trials with more
enrollment number of patients are necessary to further evaluate the safety and efficacy of this
promising double immune-checkpoints blockage therapy comparing with each of its mono‐
therapy regiments.
Finally, combinatorial clinical trials using ipilimumab with other immunotherapy agents have
shown some favorable therapeutic benefits. For example, combination of ipilimumab with
peginterferon α-2b (pegylated interferon α-2b) in patients with unresectable melanoma both
demonstrated significant increase of response rate and OS comparing with the monotherapy
arm [96, 97] in recent phase I trials.
3.2. Combined therapy inhibiting both immuno-checkpoint and MAPK signaling pathway
Checkpoint blockade immunotherapy and MAPK targeted chemotherapy have distinct
clinical profiles. For example, targeted therapy has relative higher initial response rate (~60%
for BRAFi) with rapid onset of effect, but its efficacy restrictively rely on the continuous
treatment and the therapeutic response is usually not durable due to the quick development
of acquired drug resistance. In contrast, immunotherapy has much a lower response rate (4.5%
for ipilimumab), delayed onset of effect and difficulty in predicting patient outcome, but it has
shown potentially durable responses and long-term survival benefit even off treatment. In
addition, since the MAPK pathway is not required in the process of anti-tumor immune
response, blocking MAPK signaling should not interfere with the efficacy of checkpoint
blockade immunotherapy. Therefore, it seems very rational that the combination of a MAPKi
and an immunotherapy agent such as ipilimumab or pembrolizumab can maximize the
therapeutic benefits in advance melanoma.
Interestingly, BRAF and MEK inhibition displayed an “endogenous vaccine-like” effects in
melanoma cells [98]. Cytotoxic agents like BRAFi induce tumor cell death and promote the
uptake and presentation of tumor antigens to the effector immune cells (T cells and B cells)
through antigen-presenting cells [54]. MEK inhibition, BRAFV600E RNA silencing or BRAF
inhibition by PLX4720 increases the CD4+ and CD8+ lymphocytes mediated T-cell infiltration
and reduce the level of immune-suppressants including IL-6, IL-10 or VEGF [99-101] in mice.
The expression of PD-L1 is found to be elevated in BRAFi-resistant melanoma cells and it is
mediated through the off-target activity of BRAFi in JUN and STAT3 signaling [102]. However,
Vella et al has published a paper in 2014 and stated that they have not found any impact of
dabrafenib treatment on T lymphocytes. trametinib alone or in combination with dabrafenib
has suppressed T lymphocyte proliferation, cytokine secretion and antigen-specific expansion
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in their isolated T lymphocyte and monocyte-derived dendritic cells. These findings should
be carefully tested in vivo to evaluate the clinical relevance [103].
As for the clinical practice, dose-limiting hepatotoxicity issues have led to the premature
termination of the first phase I study on combination of ipilimumab with vemurafenib
(ClinicalTrials.gov, NCT01400451). This signified the complexity of adverse effect in combined
therapy of immune-regulating agents and kinase inhibitors. Another phase I study of ipili‐
mumab plus dabrafenib, or ipilimumab plus the combination of dabrafenib with trametinib is
still active and a phase II study is exploring the safety and efficacy of sequential administration
of vemurafenib followed by ipilimumab (ClinicalTrials.gov, NCT01767454, NCT01673854).
The data of these most recent trials will be released in the near future.
4. Conclusions
Extensive efforts and remarkable progresses have been made to discover and investigate
rational approaches in combination melanoma therapy since the recent approval of MAPKi
and immune checkpoints blockade antibodies. A number of new targeted or immune drugs
for metastatic melanoma are currently under commercial development or late stage clinical
trials, some of which will likely be approved in the next few years. Quality of life for many
melanoma patients has been dramatically increased. However, significant challenges still
remain. While some clinical evidence has really raised the expectation of survivals for patients
with advanced melanoma, the benefits of combination therapy are usually accompanied by
limitations. Comprehensive genetic profile and tailored patient matching is essential for
targeted therapy, while biomarkers are critical to predict the patient immunotherapy response.
Drug-related toxicity for combination treatment usually is not a simple one-plus-one situation,
and potential drug-drug interactions, especially the combination of a targeted agent with an
immunotherapeutic agent must be carefully evaluated in order to achieve both fast and
durable responses. Adverse effects should be closely monitored and potential alternative
dosing regiments is worth further exploration. Optimized dose schedule may help to delay
the resistance development and reduce the frequency of adverse effect. For example, inter‐
mittent doses of BRAFi was able to enhance the tolerance in combination with immunotherapy,
decrease the paradoxical MAPK activation, which might be the main cause of severe toxicity
in clinical trial [104]. Solid evidence of synergistic combination in preclinical research must be
established before clinical trial conduction. In fact, with the relatively large number of available
targeted agents and immunotherapeutic agents for metastatic melanoma, the huge number of
possible drug combinations coupled with dosing sequences or schedules already presents a
significant challenge in designing proper clinical trials. To test all the possible drug combina‐
tions along with different dosing sequences clinically will not only have low benefits to
patients, but is also a huge financial burden to the society. Carefully designed, predictive
preclinical studies will be essential to provide critical supports for rational prioritization of
clinical trials using drug combinations. Finally, clear understandings of various combination
mechanisms and patient genetic profiles are critically important for the development of new
combination approaches, prediction of expected therapy response and potential side effects.
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With the rapid advances in this field, it is likely that optimal combination treatments will great
improve the management of advanced melanoma in cancer patients.
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